STAT+: Dutch health minister won’t cover a Gilead cancer drug due to the cost
In a rare move, the Dutch health ministry refused to provide coverage for a Gilead Sciences breast cancer treatment in a dispute over cost, one of the few times the government agency has taken such a step in recent years.
In explaining the decision, Health Minister Ernst Kuipers maintained that the price Gilead sought to charge for its medication, known as Trodelvy, did not justify the health benefits. The cost for each of the estimated 139 people who would be eligible for treatment would have been approximately $74,465, or a $10.4 million annual outlay.
Continue to STAT+ to read the full story…
